Almac’s rapidd continuing to accelerate early stage development 2 years on

October 25, 2011

October 2009 saw Almac launch an integrated early development service, rapiddTM, to address the issues of time, cost and attrition in early clinical candidate development by taking a lead drug development candidate to Phase I regulatory submission in under 12 months.  Two years on, Almac are pleased to report strong demand for the early stage development package.

rapiddTM works by offering a lean, flexible package, fully compliant with ICH guidelines, and integrated services between Almac and selected global CROs which is managed by Almac through a dedicated program management team.

In 2011 alone, three integrated programs have been completed with a further 5 ongoing, or in late planning stages.  Over the past two years, interest has remained strong in both the NCE and biopharmaceutical markets from a range of clients from virtual biotech companies to large pharma with both small molecule and peptide candidates.

“rapiddTM enables our clients to make significant savings against conventional lead times from careful program optimzation and avoidance of tech transfer time and other common issues which arise in a multiple partner process”, commented Denis Geffroy, VP Business Development.  “We are delighted that our rapiddTM program has proven so successful in helping to eliminate these barriers.  With our range of single-site services and capabilities, we are confident that our package brings even more added value in our clients’ pre-clinical development programs.”

In the current uncertain financial climate, Almac’s clients have benefited from the flexible approach rapiddTM offers – from taking advantage of Almac’s pre-clinical expertise to enabling payment schedules to be structured in line with agreed investor milestone payments.

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 861 3938 or e-mail: t.jervis@defacto.com.

 

Share

Back to news